T11	Exp 210 212	we
T12	Exp 222 226	that
T13	Exp 486 488	we
T14	Exp 501 512	the effects
T15	Exp 474 484	this study
T16	Exp 698 723	its nuclear translocation
T17	Exp 582 610	the transcriptional activity
T18	Exp 632 645	the hindrance
T19	Exp 750 771	The inhibitory effect
T20	Exp 835 847	the addition
T21	Exp 1055 1083	its transcriptional activity
T22	Exp 894 921	the proteolytic degradation
T23	Exp 1025 1036	the nucleus
T24	Exp 1040 1051	the absence
T25	Exp 1144 1151	neither
T26	Exp 1104 1117	The reduction
T27	Exp 1215 1227	the addition
T28	Exp 1274 1278	that
T29	Exp 1337 1342	which
T30	Exp 1308 1321	the treatment
T31	Exp 1424 1438	the regulation
T32	Exp 1245 1255	This study
R4	Coref Anaphora:T16 Antecedent:T33
R5	Coref Anaphora:T21 Antecedent:T9
R6	Coref Anaphora:T29 Antecedent:T34
T1	Protein 20 52	S-adenosylhomocysteine hydrolase
T2	Protein 172 184	IkappaBalpha
T3	Protein 288 320	S-adenosylhomocysteine hydrolase
T4	Protein 384 411	tumor necrosis factor-alpha
T5	Protein 416 433	interleukin-1beta
T6	Protein 649 652	p65
T7	Protein 654 659	Rel-A
T8	Protein 925 937	IkappaBalpha
T9	Protein 947 958	IkappaBbeta
T10	Protein 1121 1133	IkappaBalpha
T33	Exp 685 694	reduction
T34	Exp 1325 1333	diseases
